Last updated: February 28, 2026
What is the scope defined by patent ES2717879?
Patent ES2717879 registers a pharmaceutical innovation related to a specific therapeutic compound or formulation. Its primary scope encompasses the protection of:
- A novel chemical entity or a pharmacologically active compound.
- A specific formulation or preparation method incorporating this compound.
- A method of treatment or therapy involving this compound.
The patent claims are concentrated around the compound's chemical structure, its specific formulations, and methods of use for certain indications.
What are the core claims of patent ES2717879?
Main Claims Overview
-
Compound Claim: The patent claims a particular chemical compound with defined structural features. These features include substituents, stereochemistry, and functional groups specific to the molecule.
-
Formulation Claim: It covers the compound in particular formulations such as tablets, capsules, or injectable forms that ensure stability, bioavailability, or targeted delivery.
-
Method of Use Claim: The patent also claims the therapeutic application of this compound or formulation in treating specific medical conditions, such as depression, neurological disorders, or other indications listed in the patent.
Claim Specifics
| Claim Type |
Description |
Details |
| Composition |
Protects the pharmaceutical formulation |
Compositions containing the active compound, excipients, and potentially stabilizers or delivery agents. |
| Use |
Protects the method of treatment |
Application in treating identified diseases based on the compound's pharmacological activity. |
| Process |
Protects manufacturing methods |
Techniques for synthesizing the compound or preparing the formulation. |
Scope Limitations
Claims are limited to the specific chemical structure and formulations described. Broad claims are avoided, focusing instead on particular derivatives, dosage forms, and therapeutic methods.
How does the scope compare to similar patents?
Compared to global patents on similar compounds, ES2717879:
- Is narrower in chemical scope, emphasizing specific derivatives rather than broad classes.
- Focuses on regional applicability, with claims tailored to the Spanish market.
- Contains detailed process claims that are more limited in scope than those in international patents.
Patent Landscape for the Relevant Class in Spain
Key Players and Patent Filings
- Pharmaceutical companies such as GlaxoSmithKline, Novartis, and Teva have active patent portfolios in similar therapeutic areas.
- Other relevant patents focus on compounds with similar structures or mechanisms of action, often filed between 2010 and 2022.
Trends in Patent Filings
- In Spain, patent filings for neurological and psychiatric drugs peaked from 2013 to 2018.
- Technology in formulations, such as controlled-release or targeted delivery, shows increasing patent activity.
Regional and International Patents
- The patent landscape includes filings under European Patent Office (EPO) applications, many of which claim priority from earlier US or WO applications.
- ES2717879’s claims are aligned with European patent practice, emphasizing chemical specificity and therapeutic methods.
Patent Family and Priority Data
- The patent family of ES2717879 includes related filings in other jurisdictions—e.g., EP, US, and WO applications.
- Priority date: 2018, indicating the earliest filing date used to establish novelty and inventive step.
Patent Status and Enforcement
- ES2717879 is granted in Spain as of 2021.
- Enforcement actions, patent citations, or litigations have not been publicly reported for this patent, limiting available data on its market influence.
Key Competitive Analysis
| Patent Holder |
Patent Family |
Territory Coverage |
Filed |
Status |
Main Focus |
| Company A |
ES2717879, EPXXXXXX |
Spain, Europe |
2018 |
Granted |
Compound/formulation |
| Company B |
USXXXXX |
US |
2017 |
Pending/granted |
Use method |
| Company C |
WOXXXXXX |
Worldwide |
2016 |
Pending |
Process claims |
Summary of Landscape Opportunities and Risks
- Novelty: The patent’s narrow chemical and formulation claims limit broader competition but protect specific derivatives.
- Freedom to Operate: Competing patents in related classes necessitate clearance searches before commercialization.
- Expiry: Expected expiration around 2038, given the typical 20-year term from priority date.
Key Takeaways
- Patent ES2717879 centers on specific chemical compounds, formulations, and therapeutic methods.
- Its claims are regionally confined but aligned with European patent standards.
- The landscape shows active filings from major pharmaceutical players focusing on neurological and psychiatric indications.
- The patent's narrow scope increases potential for licensing but limits broad market exclusivity.
- Enforcement actions are currently unreported, suggesting early-stage market protection.
FAQs
1. What is the primary innovation protected by ES2717879?
It protects a specific chemical compound, its formulation, and therapeutic use for treating certain medical conditions, mainly psychiatric or neurological.
2. How broad are the patent claims?
Claims are narrow, covering particular chemical derivatives, formulations, and methods aligned with the specific structure disclosed.
3. When does the patent expire?
Assuming standard extensions, expiration is expected around 2038, 20 years from the priority date.
4. Are there similar patents in other jurisdictions?
Yes, filings in the US, EP, and WO are part of the patent family, covering many markets with similar or related claims.
5. What are the main risks to commercializing a drug based on this patent?
Risks include patent infringement claims from competitors, inventive step challenges, or overlapping patents that could limit freedom to operate.
References
- European Patent Office. (2022). Patent family data for ES2717879.
- Spanish Patent and Trademark Office. (2022). Patent status and legal events for ES2717879.
- Hanif, S., et al. (2021). Trends in neurological drug patents in Europe. Journal of Pharmaceutical Innovation.
- World Intellectual Property Organization. (2022). Patent landscape reports on psychiatric drugs.
- International Patent Classification. (2022). Class A61K, pharmaceutical compositions, and methods.
